Most “drug interactions” aren’t exotic at all. They’re dinner. Or breakfast. Or the innocent-looking supplement aisle.
And while clinicians think in terms of CYP enzymes and receptor binding, patients often think in simpler terms: Can I […]
And while clinicians think in terms of CYP enzymes and receptor binding, patients often think in simpler terms: Can I […]
When a patient asks ChatGPT whether Ozempic or Mounjaro is better for weight loss, they get an answer. Not a
Drug safety surveillance has a new blind spot. Millions of patients are now asking ChatGPT, Gemini, Claude, and Perplexity about
Prescribing information is the most legally precise document in medicine. Every word in a package insert has survived FDA review,
When Pfizer launched Paxlovid in late 2021, the company had a distribution problem, a supply chain problem, and a rebound
Alcohol has a way of slipping into medical conversations whether clinicians invite it or not. Patients rarely ask about it
Pregnancy is one of those states where pharmacology becomes less about mechanism diagrams and more about uncertainty management. The questions
There’s a persistent habit in medicine—and especially in patient questions online—of treating antibiotics as if they were interchangeable with everyday
A patient in Phoenix types ‘is Ozempic safe for someone with a history of pancreatitis?’ into ChatGPT at 11 p.m.
In late 2023, a patient with type 2 diabetes asked ChatGPT whether semaglutide could eliminate the need for insulin entirely.
In 2023, a patient asked ChatGPT whether she could take Eliquis with ibuprofen. ChatGPT told her the combination was generally
How drug brands fought off-label prescribing to survive: real FDA cases, litigation wins, and what AI monitoring means for pharmacovigilance
Get sharp analysis on AI-generated drug information, off-label curiosity, pharmacovigilance blind spots, and the shifting intersection of pharma, search, and large language models. No fluff. Just the signals that matter.